"EMA’s human medicines committee (CHMP) has concluded that a booster dose of the COVID-19 vaccine Spikevax (from Moderna) may be considered in people aged 18 years and above," the statement reads.
The third dose of Spikevax administered six to eight months after the second dose resulted in an increase in antibodies in adults whose antibody levels were waning, according to the regulator.
The side effects after the booster are similar to those that may occur after the second dose, the EMA noted.
The EMA has already approved the third dose of BioNTech/Pfizer vaccine earlier in October.
The decision on including the third dose in the vaccination plan can be made by European countries independently based on the epidemiological situation.